StockData

Ironwood Pharmaceuticals vs Xeris Biopharma

IRWD and XERS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How IRWD and XERS compare

Xeris Biopharma is the larger company, worth 3.8 times as much as Ironwood Pharmaceuticals ($3.1B against $801M).

Xeris Biopharma grew revenue faster over the last twelve months (36.3% versus 26.2% for Ironwood Pharmaceuticals).

Ironwood Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 33.4% compared with −5.1% at Xeris Biopharma.

Ironwood Pharmaceuticals scores higher on the StockData Score (12 against 10 for Xeris Biopharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricIRWDXERS
Size and price
Market cap$801M$3.1B
Share price$4.85$16.80
Change, 1 year43.9%134%
Change, 5 years−56.5%674%
Beta (5Y)1.050.27
Employees100435
StockData Score
Total score12 (better)10
Valuation score6 (better)0
Growth score24 (better)
Performance score23 (better)
Health score23 (better)
Dividend score00
Valuation
P/E6.3×–
P/S2.1× (better)9.1×
EV/EBITDA3.1× (better)84.2×
Fair value$12.87–
Margin of safety62.3%–
Growth
Revenue growth (TTM)26.2%36.3% (better)
Revenue growth, 5Y average−5.3%70.2% (better)
EPS growth, 5Y average−25.6%–
Profitability
Gross margin–86.6%
Operating margin60.1% (better)10.9%
Net margin33.4% (better)−5.1%
Return on invested capital–22.1%
Financial health
Net debt / EBITDA–3.45
Interest coverage7.2× (better)1.3×
Current ratio6.06 (better)1.45
Altman Z-score−1.913.33 (better)
Piotroski F-score68 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions97.2%59.4%
Held by insiders16.0%5.2%
Insider net buying, 12 months−$22.6M−$5.8M (better)
Short interest, % of float10.7%5.2%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.